First Compassionate Special Permit (CSP) Patient in Philippines Improved Significantly 35 hours After First Injection of Leronlimab and Released 3 Days Later Other OTC:CYDY

First Compassionate Special Permit (CSP) Patient in Philippines Improved Significantly 35 hours After First Injection of Leronlimab and Released 3 Days Later Other OTC:CYDY

News Highlights

VANCOUVER, Washington, April 05, 2021 (News) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the first Compassionate Special Permit (CSP) patient in the Philippines improved significantly 35 hours after receiving a 700 mg injection of Vyrologix™ under a licensed physician’s request for CSP to treat COVID-19 patients.

The CSP patient spent 10 days on high flow oxygen, was treated with multiple doses of dexamethasone and then tocilizumab during that period and did not improve. The physician in charge of the patient was pleased to report that, 35 hours after the subcutaneous injection of leronlimab, the patient was removed from high-flow oxygen and was breathing on his own. The patient was discharged from the hospital on Saturday, April 3.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are very pleased to see Vyrologix™ (leronlimab) used in the first patient in the Philippines. We are ready to ship more product for any patients who request leronlimab under CSP in the Philippines. I want to reiterate our commitment to the Philippines of at least 100,000 doses upon the FDA Philippines granting Emergency Use Authorization (EUA). We believe this anecdotal data and more than 90 approved eINDs (emergency IND) in U.S. along with the results of our CD12 of 384 mITT (modified intent to treat), double blinded study that had 82% reduction in 14-day mortality of critically ill, mechanically ventilated patients with statistically significant p-value is a compelling reason to move forward with the EUA request in the Philippines. We are very thankful our partners at Chiral Pharma were able to help with this patient.”

About Leronlimab (PRO 140) The U.S. Food and Drug Administration (FDA) granted CytoDyn Fast Track designation to explore two potential indications using leronlimab to treat HIV and metastatic cancer. The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC). Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor important in HIV infection, tumor metastases, and other diseases, including NASH (Nonalcoholic Steatohepatitis). Leronlimab has been studied in 11 clinical trials involving more than 1,200 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients). 

Leronlimab is a viral-entry inhibitor in HIV/AIDS. It masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Nine clinical trials have demonstrated leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent with fewer side effects and less frequent dosing requirements than currently used daily drug therapies. 

Cancer research has shown CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. As a result, CytoDyn is conducting two Phase 2 human clinical trials, one in mTNBC, which was granted Fast Track designation by the FDA in 2019, and a second in a basket trial which encompasses 22 different solid tumor cancers.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. After completing two clinical trials with COVID-19 patients (a Phase 2 and a Phase 3), CytoDyn initiated a Phase 2 investigative trial for post-acute sequelae of SARS COV-2 (PASC), also known as COVID-19 Long-Haulers. This trial will evaluate the effect of leronlimab on clinical symptoms and laboratory biomarkers to further understand the pathophysiology of PASC. It is currently estimated that between 10-30% of those infected with COVID-19 develop long-term sequelae. Common symptoms include fatigue, cognitive impairment, sleep disorders, and shortness of breath. If this trial is successful, CytoDyn plans to pursue clinical trials to evaluate leronlimab’s effect on immunological dysregulation in other post-viral syndromes, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

CytoDyn is also conducting a Phase 2 clinical trial for NASH to evaluate the effect of leronlimab on liver steatosis and fibrosis. Preclinical studies revealed a significant reduction in NAFLD and a reduction in liver fibrosis using leronlimab. There are currently no FDA approved treatments for NASH. NASH is a leading cause of liver transplant. About 30 to 40 percent of adults in the U.S. live with NAFLD, and 3 to 12 percent of adults in the U.S. live with NASH.

About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications using leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH.

CytoDyn has successfully completed a Phase 3 pivotal trial using leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn has been working diligently to refile its Biologics License Application (“BLA”) for this HIV combination therapy since receiving a Refusal to File in July 2020 and subsequently meeting with the FDA telephonically to address their written guidance concerning the filing. CytoDyn expects to refile its BLA in the first half of the calendar year 2021 or shortly thereafter.

CytoDyn also completed a Phase 3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension approval. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce the viral burden in people infected with HIV. Moreover, a Phase 2 clinical trial demonstrated that leronlimab monotherapy could prevent viral escape in HIV-infected patients; several patients on leronlimab’s Phase 2 monotherapy extension arm have remained virally suppressed for more than six years. There have been no strong safety signals identified in patients administered leronlimab in multiple disease spectrums, including patients with HIV, COVID-19 and Oncology.

CytoDyn is also conducting a Phase 2 clinical trial with leronlimab in mTNBC, a Phase 2 basket trial in solid tumor cancers (22 different cancer indications), Phase 2 investigative trial for post-acute sequelae of SARS COV-2, also known as COVID-19 Long-Haulers, and a Phase 2 clinical trial for NASH. CytoDyn has already completed two trial in COVID-19 patients (a Phase 2 and a Phase 3) and is in the process of conducting an additional COVID-19 Phase 3 trial for mechanically ventilated critically ill COVID-19 patients. More information is at www.cytodyn.com

Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to provide positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company’s cash position, (ii) the Company’s ability to raise additional capital to fund its operations, (iii) the Company’s ability to meet its debt obligations, if any, (iv) the Company’s ability to enter into partnership or licensing arrangements with third parties, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company’s clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CONTACTSInvestors: Michael MulhollandOffice: 360.980.8524, ext. 102mmulholland@cytodyn.com 

  • Check the latest Health news updates and information.
  • Please share this news First Compassionate Special Permit (CSP) Patient in Philippines Improved Significantly 35 hours After First Injection of Leronlimab and Released 3 Days Later Other OTC:CYDY with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
SCAM ALERT: Pretenders steal money and claim link to Orange County Sheriff’s Office |  Latest news

SCAM ALERT: Pretenders steal money and claim link to Orange County Sheriff’s Office | Latest news

Source starexponent.com “Do not, under any circumstance, provide money or personal identifying information to someone that calls you who is reportedly a ...
Draghi plans € 220 billion overhaul of Italy’s economy

Draghi plans € 220 billion overhaul of Italy’s economy

The Draghi plan will focus on improving the efficiency of Italy’s electricity grid, investing in hydrogen power projects and other renewable energy sources, ...
Kudlow: Biden’s infrastructure spending bill will ‘destroy’ the economy

Kudlow: Biden’s infrastructure spending bill will ‘destroy’ the economy

WATCH LARRY KUDLOW’S FULL MONOLOGUE HERE And of course, the vaccines are reopening the economy, and a reopening economy with tax incentives is booming. ...
Palmetto MolDx Issues Foundational Coverage for Molecular Testing in Solid Organ Allograft Rejection Nasdaq:CDNA

Palmetto MolDx Issues Foundational Coverage for Molecular Testing in Solid Organ Allograft Rejection Nasdaq:CDNA

News Highlights SOUTH SAN FRANCISCO, Calif., April 22, 2021 (News) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the ...
Guide on what can be Done With Your Old Laptop

Guide on what can be Done With Your Old Laptop

And that raises a good question: How do you go about finding a new home for an old laptop? With Earth Day approaching, here are a few eco-friendly options to ...
Facebook pulls business page for Mattoon Burger King

Facebook pulls business page for Mattoon Burger King

It prevents a Burger King franchise from opening within a 20-mile radius of the Mattoon Burger King. Owners think this may be connected to their lawsuit ...
Breaking News:5 ways in which companies can be more aggressive in relation to climate change

Breaking News:5 ways in which companies can be more aggressive in relation to climate change

Disclose carbon footprints But a forthcoming report expected in mid-May by the World Wildlife Fund (WWF) will show that only 61 of those companies with ...
Republican Party doctors and healthcare providers ask Pelosi when the House’s COVID restrictions will be lifted with questioned members

Republican Party doctors and healthcare providers ask Pelosi when the House’s COVID restrictions will be lifted with questioned members

The group pointed out that the “promise of a return to pre-pandemic normalcy was the goal” and declared that Congress “must set an example” since so many of ...
American Financial Resources Restores Conventional OTC Financing

American Financial Resources Restores Conventional OTC Financing

Related Links SOURCE American Financial Resources, Inc. “We are proud to offer a full suite of One-Time Close products, and support our business partners ...
Oprah Winfrey turns down talks of police raid and arrest

Oprah Winfrey turns down talks of police raid and arrest

The 66-year-old talk show host and media mogul became one of Twitter’s top trending topics on Tuesday night after rumors began circulating on social media ...
Show next
Compsmag - Latest News from tech, business and health
Logo